NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的血液製劑產業(2020年∼2027年)

China Blood Product Industry Report, 2020-2027

出版商 ResearchInChina 商品編碼 999582
出版日期 內容資訊 英文 180 Pages
商品交期: 最快1-2個工作天內
價格
中國的血液製劑產業(2020年∼2027年) China Blood Product Industry Report, 2020-2027
出版日期: 2021年03月19日內容資訊: 英文 180 Pages
簡介

中國的血液製劑的批次放行數量,與前一年同期比較1增加2.7%達1億131萬個,並繼續成長。由於國民醫療保險制度的對象之醫藥品調整,幾乎全部的血液製劑臨床使用的範圍和償付率飛躍性擴大,血液製劑市場更加擴大。

近幾年,中國血液製劑製造商M&A活性化。大企業主要利用M&A,建立自己的血漿站,借助補充擴張模式實現快速成長。M&A是他們長期性策略計劃的重要部分。

本報告提供中國的血液製劑產業的相關調查,市場規模,政策,現狀,市場結構,需求與供給,主要企業的簡介,預測等資訊。

目錄

第1章 血液製劑

  • 定義
  • 分類
  • 重組血液製劑
  • 產業鏈
  • 特徵

第2章 中國的血液製劑市場

  • 政策
  • 現狀
  • 市場結構
  • 需求與供給
    • 供給
    • 需求
  • 市場規模
  • 競爭模式

第3章 中國的血液製劑市場區隔

  • 人體血清蛋白
    • 現狀
    • 競標價格
    • 市場結構
    • 競爭模式
    • 預測
  • 靜脈注射用人類免疫球蛋白(pH4)
    • 現狀
    • 競標價格
    • 競爭模式
    • 預測
  • 凝固第八凝血因子
    • 現狀
    • 競標價格
    • 競爭模式
    • 預測
  • 人B型肝炎免疫球蛋白
    • 現狀
    • 競標價格
    • 競爭模式
  • 人類免疫球蛋白
    • 現狀
    • 競標價格
    • 競爭模式
  • 人凝血素原複合體
    • 現狀
    • 競標價格
    • 競爭模式
  • 人破傷風免疫球蛋白
    • 現狀
    • 競標價格
    • 競爭模式
  • 人狂犬病免疫球蛋白
    • 現狀
    • 競標價格
    • 競爭模式

第4章 主要企業

  • China Biologic Products (CBPO)
  • Hualan Biological Engineering Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Beijing Tiantan Biological Products
  • Guangdong Shuanglin Bio-Pharmacy
  • Jiangxi Boya Bio-Pharmaceutical
  • Weiguang Biological Products
  • Beijing Bohui Innovation Technology
  • Wuhan ZhongyuanRuide Biological Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Shanxi Kangbao Biological Product Co., Ltd.
  • Green Cross China
  • Nanyue Biopharming Corporation Ltd.

第5章 摘要與預測

  • 概要
  • 開發趨勢
    • 繼續熱潮的產業
    • 整合產業的加速,更高漲集中
    • 左右產業的血漿採取數量和血漿站數
    • 慢慢增加的血漿採取數量
    • 為了強化競爭力企業著重新產品的研究開發,血漿的全面利用更進步
    • 下游需求對產業的刺激
    • 醫療制度改革加深,醫療保險制度階段性完成對產業成長的貢獻
    • 由於COVID-19大流行對國內企業的開發機會
目錄

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which has further opened up the blood product market. In 2020, the lot release volume of blood products in China sustained growth, hitting 101.31 million bottles, a year-on-year upsurge of 12.7%.

Wherein, the lot release volume of human albumin rose 14.78% on an annualized basis, making up 60%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 12.92% in the total showed a year-on-year increase of 11.78%; that of human tetanus immunoglobulin soared by 76.7% and accounted for 6.9%; other products like human fibrinogen, human prothrombin complex and human coagulation factor VIII took relatively low shares.

The Health Commission of Yunnan Province proposed to set up 24 plasma collection stations (adding 20 new ones based on the 4 pilot ones) across the province, according to the Plan of Yunnan Province for Setting up Plasma Collection Stations (2020-2023) (Exposure Draft) it issued in December 2020. Currently, Shanghai Blood Products under Beijing Tiantan Biological Products has 2 pilot stations operated in Yunnan, having collected a total of around 42 tons. Also, the document indicates blood product companies that construct production bases in Yunnan will be given priority to build. With its plasma station expansion plan, Yunnan may set the pace in loosening the restrictions on new plasma stations. On one estimate, China had boasted 273 plasma collection stations by the end of 2020.

In 2020, the pandemic suspended plasma collection in China for two months, stopping collection volume growth. Chinese Academy of Medical Sciences predicted a like-on-like slump of 22%, or 1,000 tons, in plasma collection volume in the first half of 2020.

Companies with more plasma stations, such as Beijing Tiantan Biological Products, Shanghai RAAS Blood Products, China Biologic Products and Hualan Biological Engineering gather pace and will scramble for larger shares on the strength of their great ability to collect plasma, promising their far higher industry status. In 2019, Beijing Tiantan Biological Products, Hualan Biological Engineering, China Biologic Products and Shanghai RAAS Blood Products took a higher combined market share of up to 34.47%.

In recent years, there were an increasing number of mergers and acquisitions among blood products companies in China. Leaders roared ahead mainly by way of mergers and acquisitions, an expansion model supplemented by self-built plasma stations. Mergers and acquisitions have been a key part of their long-term strategic plans.

On January 28, 2020, Southern Shuanglin Bio-Pharmacy made an announcement that it would merge with Harbin Pacific Biopharmaceutical and restructure it, and raise funds. Southern Shuanglin Bio-Pharmacy now has 13 plasma collection stations, collecting roughly 400 tons in 2019, compared with Harbin Pacific Biopharmaceutical which owns 10 stations collecting 240 tons in 2019. Moreover, Southern Shuanglin Bio-Pharmacy and Xinjiang Deyuan Bioengineering forged a strategic partnership in which Xinjiang Deyuan Bioengineering promises to provide over 180-ton plasma for Southern Shuanglin Bio-Pharmacy every year, totaling more than 900 tons for the five years to come. Southern Shuanglin Bio-Pharmacy is thus expected to be a first-echelon player in the industry.

“China Blood Product Industry Report, 2020-2027” highlights the following:

  • China blood product industry (policy, status quo, market structure, supply & demand, market size, competitive pattern);
  • China blood product market segments (status quo, bid price, competitive pattern);
  • 13 blood product companies (operation, revenue structure, gross margin, blood product business, etc.);
  • Summary and forecast.

Table of Contents

1. Blood Products

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 Recombinant Blood Products
  • 1.4 Industry Chain
  • 1.5 Features

2. China Blood Product Market

  • 2.1 Policies
  • 2.2 Status Quo
  • 2.3 Market Structure
  • 2.4 Supply and Demand
    • 2.4.1 Supply
    • 2.4.2 Demand
  • 2.5 Market Size
  • 2.6 Competitive Pattern

3. China Blood Product Market Segments

  • 3.1 Human Albumin
    • 3.1.1 Status Quo
    • 3.1.2 Bid Price
    • 3.1.3 Market Structure
    • 3.1.4 Competitive Pattern
    • 3.1.5 Prospects
  • 3.2 Human Immunoglobulin (pH4) for Intravenous Injection
    • 3.2.1 Status Quo
    • 3.2.2 Bid Price
    • 3.2.3 Competitive Pattern
    • 3.2.4 Prospects
  • 3.3 Coagulation Factor VIII
    • 3.3.1 Status Quo
    • 3.3.2 Bid Price
    • 3.3.3 Competitive Pattern
    • 3.3.4 Prospects
  • 3.4 Human Hepatitis B Immunoglobulin
    • 3.4.1 Status Quo
    • 3.4.2 Bid Price
    • 3.4.3 Competitive Pattern
  • 3.5 Human Immunoglobulin
    • 3.5.1 Status Quo
    • 3.5.2 Bid Price
    • 3.5.3 Competitive Pattern
  • 3.6 Human Prothrombin Complex
    • 3.6.1 Status Quo
    • 3.6.2 Bid Price
    • 3.6.3 Competitive Pattern
  • 3.7 Human Tetanus Immunoglobulin
    • 3.7.1 Status Quo
    • 3.7.2 Bid Price
    • 3.7.3 Competitive Pattern
  • 3.8 Human Rabies Immunoglobulin
    • 3.8.1 Status Quo
    • 3.8.2 Bid Price
    • 3.8.3 Competitive Pattern

4. Major Enterprises

  • 4.1 China Biologic Products (CBPO)
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 R&D Investment
    • 4.1.6 Blood Products Business
    • 4.1.7 Guizhou Taibang Biological Products Co., Ltd.
    • 4.1.8 Shandong Taibang Biological Products Co., Ltd.
    • 4.1.9 Xi'an Huitian Blood Products Co., Ltd.
  • 4.2 Hualan Biological Engineering Co., Ltd.
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D Investment
    • 4.2.6 Blood Products Business
    • 4.2.7 Development Strategy
  • 4.3 Shanghai RAAS Blood Products Co., Ltd.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D Investment
    • 4.3.6 Blood Products Business
    • 4.3.7 Development Strategy
  • 4.4 Beijing Tiantan Biological Products
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 R&D Investment
    • 4.4.6 Blood Products Business
    • 4.4.7 Chengdu Rongsheng
    • 4.4.8 Dynamics
  • 4.5 Guangdong Shuanglin Bio-Pharmacy
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Gross Margin
    • 4.5.4 R&D Investment
    • 4.5.5 Blood Products Business
    • 4.5.6 Dynamics
  • 4.6 Jiangxi Boya Bio-Pharmaceutical
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D Investment
    • 4.6.6 Blood Products Business
    • 4.6.7 Dynamics
  • 4.7 Weiguang Biological Products
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 R&D Investment
    • 4.7.6 Blood Products Business
    • 4.7.7 Development Strategy
  • 4.8 Beijing Bohui Innovation Technology
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 R&D Investment
    • 4.8.6 Blood Products Business
    • 4.8.7 Development Strategy
    • 4.8.8 Dynamics
  • 4.9 Wuhan ZhongyuanRuide Biological Products Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Blood Products Business
  • 4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • 4.10.1 Profile
    • 4.10.2 Blood Products Business
    • 4.10.3 Development Strategy
  • 4.11 Shanxi Kangbao Biological Product Co., Ltd.
    • 4.11.1 Profile
    • 4.11.2 Blood Products Business
  • 4.12 Green Cross China
    • 4.12.1 Profile
    • 4.12.2 Blood Products Business
  • 4.13 Nanyue Biopharming Corporation Ltd.
    • 4.13.1 Profile
    • 4.13.2 Blood Products Business
    • 4.13.3 Development Strategy

5. Summary and Forecast

  • 5.1 Summary
  • 5.2 Development Trends
    • 5.2.1 The Industry Continues to Boom
    • 5.2.2 Industry Integration Speeds Up, Concentration Rises Further
    • 5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
    • 5.2.4 Plasma Collection Volume Increases Progressively
    • 5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise
    • 5.2.6 Downstream Demand Stimulates the Industry
    • 5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Growth of the Industry
    • 5.2.8 COVID-19 Pandemic Brings Development Opportunities to Domestic Companies